Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin

Oncoimmunology. 2021 Aug 2;10(1):1957215. doi: 10.1080/2162402X.2021.1957215. eCollection 2021.

Abstract

Gliomas are heavily infiltrated with immune cells of myeloid origin. Past studies have shown that high-grade gliomas have a higher proportion of alternatively activated and suppressive myeloid cells when compared to low-grade gliomas, which correlate with poor prognosis. However, the differences in immune cell phenotypes within high-grade gliomas (between grade 3 and grade 4 or GBM) are relatively less explored, and a correlation of phenotypic characteristics between immune cells in the blood and high-grade tumors has not been performed. Additionally, myeloid cells of granulocytic origin present in gliomas remain poorly characterized. Herein, we address these questions through phenotypic characterizations of monocytes and neutrophils present in blood and tumors of individuals with glioblastoma (GBM, IDH-wild type) or grade 3 IDH-mutant gliomas. We observe that neutrophils are highly heterogeneous among individuals with glioma, and are different from healthy controls. We also show that CD163 expressing M2 monocytes are present in greater proportions in GBM tissue when compared to grade 3 IDH-mutant glioma tissue, and a larger proportion of granulocytic myeloid-derived suppressor cells are present in grade 3 IDH-mutant gliomas when compared to GBM. Finally, we demonstrate that the expression levels of CD86 and CD63 showed a high correlation between blood and tumor and suggest that these may be used as possible markers for prognosis.

Keywords: CD163; CD63; CD86; Glioblastoma; immunosuppression; neutrophils.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytoma* / genetics
  • Brain Neoplasms* / genetics
  • Glioblastoma* / genetics
  • Glioma*
  • Humans
  • Isocitrate Dehydrogenase / genetics

Substances

  • Isocitrate Dehydrogenase

Grants and funding

This work was supported by Biodesign and Bioengineering Initiative (Phase II), Department of Biotechnology, Govt. of India. It was also funded by the Dr. Vijaya and Rajagopal Rao laboratory for Biomedical Engineering at IISc, and R.I. Mazumdar Young Investigator position (to SJ). This work was also supported by the institutional funds from the Mazumdar Shaw Medical Foundation, SERB, Govt. of India (CRG/2018/002523, DS), andICMR, Govt. of India (BIC/11(36)/2014, RG).